Large-Scale Evaluation of a Clinical Decision Tree for the Management of Low-Energy Thoracic and Lumbar Vertebral Compression Fractures. (PALMTREE)
研究概览
详细说明
Percutaneous vertebroplasty was first described in France in 1987 . Since its introduction, this minimally invasive technique has become widely accepted and is now a routine treatment for low-energy vertebral compression fractures (LEVCFs), also referred to as vertebral "crush" fractures. Clinical outcomes, including pain relief, analgesic consumption, and quality of life assessed through self-administered questionnaires, are commonly used to evaluate the effectiveness of the procedure.
Over the past 20 years, several randomized controlled trials (RCTs) have been conducted to assess the efficacy of vertebroplasty compared with non-surgical management (including bracing and placebo treatment). Two recent meta-analyses identified 13 RCTs published by January 2019 and 14 RCTs by July 2020, reaching different conclusions.
In 2019, Lou et al. concluded that percutaneous vertebroplasty was effective and safe only in patients with acute low-energy vertebral compression fractures associated with persistent and severe pain. In contrast, Lainez Ramos-Bossini et al. concluded in 2020 that vertebroplasty offered significant benefits compared with non-surgical treatment, including short-term pain relief and improved quality of life. However, these benefits appeared more limited when vertebroplasty was compared with placebo treatment.
The conclusion of the Cochrane review published by Buchbinder et al. in 2018 remains relevant today: "Based on high- to moderate-quality evidence, our updated review does not support a role for vertebroplasty in the routine management of acute or subacute osteoporotic vertebral fractures." .
Furthermore, recent studies involving large patient cohorts have reported a significant rate of complications associated with percutaneous vertebroplasty. Among 1,932 patients, 166 (8.6%) experienced a complication, including 53 minor complications (2.7%) and 95 major complications (4.9%) . Patient selection appears to play a crucial role in the occurrence of complications, as suggested by Scheyerer et al. in a recent literature review .
The authors identified both non-modifiable and modifiable risk factors for perioperative and postoperative complications, including: age >90 years, male sex, low level of daily activity, partial or complete dependency, hospitalization, high American Society of Anesthesiologists (ASA) classification, Parkinson's disease, chronic obstructive pulmonary disease (COPD), arterial hypertension, renal failure, liver failure, coagulopathies, chronic steroid use, preoperative sepsis, and hypoalbuminemia (<3.5 g/dL) .
Simple preoperative markers, such as serum albumin levels, should therefore be considered when deciding whether vertebroplasty is appropriate for the treatment of low-energy vertebral compression fractures.
To improve the clarity and standardization of the management of patients presenting with low-energy vertebral compression fractures ("crush" fractures), we developed a clinical decision tree based on patient age, MRI findings, pain severity assessed using a Visual Analog Scale (VAS), and the extent of radiological deformity.
THE AIME OF THE STUDY IS : To evaluate the clinical and radiological healing outcomes of patients managed according to a clinical decision tree for one or more low-energy vertebral compression fractures (LEVCFs) at Grenoble Alpes University Hospital between January 1, 2022, and March 31, 2025.
Design of the study :Single-center prospective observational cohort study with no control group.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Mehdi BOUDISSA, Pr
- 电话号码:0476763275
- 邮箱:mboudissa@chu-grenoble.fr
研究联系人备份
- 姓名:Sarah KASSAR-UNEISI, Pharm D
- 电话号码:0476767524
- 邮箱:suneisi@chu-grenoble.fr
学习地点
-
-
-
La Tronche、法国、38700
- GRENOBLE ALPES UNIVERSITY HOSPITAL
-
首席研究员:
- Mehdi BOUDISSA, Pr
-
接触:
- Sarah PI KASSAR-UNEISI, Pharm D
- 电话号码:0476767524
- 邮箱:suneisi@chu-grenoble.fr
-
接触:
- Mehdi PI BOUDISSA, Pr
- 电话号码:0476763275
- 邮箱:mboudissa@chu-grenoble.fr
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Age > 50 years
- One or more low-energy vertebral compression fractures (LEVCFs) confirmed by MRI
- Fractures located between T7 and L5
- Compression fractures classified as A1.1, A1.2, or A1.3 according to the Magerl classification [15]
- Management in accordance with the clinical decision tree
- Vertebroplasty performed by an interventional radiologist, orthopedic surgeon, or neurosurgeon
- Vertebral augmentation performed by an orthopedic surgeon or neurosurgeon, with or without navigation assistance
- Conservative treatment consisting of a lumbar brace worn during daytime, with duration individualized according to the patient's needs, and physiotherapy initiated between 45 and 90 days after treatment, including core stabilization, stretching, and strengthening of the posterior muscle chain and abdominal muscles, based on active rehabilitation rather than manual therapy (no massage therapy).
Exclusion Criteria:
- Pregnant or breastfeeding women
- Individuals under administrative or judicial supervision
- Age < 50 years or > 90 years
- Pathological vertebral fracture
- Presence of other osteoporotic fractures during the study follow-up period (6 months)
- Non-compliance with the clinical decision tree
- Dementia or cognitive impairment preventing data collection at the final follow-up (telephone interview), assessed using the Mini-Cog test (score < 3 = exclusion)
- Refusal to participate during the telephone interview or inability to provide non-opposition (e.g., under legal guardianship)
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Evaluate the clinical and radiological healing outcomes of patients managed according to a clinical decision tree for one or more low-energy vertebral compression fractures (LEVCFs)
大体时间:1 year
|
Radiological fracture healing, assessed on standard radiographs based on cortical continuity, disappearance of fracture lines, absence of progressive kyphosis, and absence of osteosynthesis hardware-related complications.
Fracture healing will be classified as complete, partial, or absent.
|
1 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Assessment of radiological deformity.
大体时间:1 year
|
Assessment of radiological deformity (vertebral kyphosis [VK], regional kyphosis [RK], and spinal canal narrowing) in patients managed according to the clinical decision tree
|
1 year
|
|
Assessment of clinical outcomes
大体时间:1 year
|
EVA -pain score
|
1 year
|
|
Assessment of clinical outcomes
大体时间:1 year
|
quality of life EQ5D 3 L
|
1 year
|
|
Assessment of clinical outcomes
大体时间:1 year
|
Mobility -Parker Mobility Score
|
1 year
|
|
Assessment of clinical outcomes
大体时间:1 year
|
Analysis of risk factors for failure of conservative treatment
|
1 year
|
|
Assessment of vertebroplasty cement filling quality
大体时间:1 year
|
(Garnier classification)
|
1 year
|
|
Assessment of fracture healing and associated factors
大体时间:1 year
|
Evaluation of time to fracture healing, comparing conservative versus surgical treatment (measured in days; for surgical treatment, time is calculated from the date of surgery)
|
1 year
|
|
Assessment of fracture healing and associated factors
大体时间:1 year
|
Assessment of the effect of calcium and vitamin D supplementation on fracture healing and the rate of refracture or new fractures.
|
1 year
|
|
Assessment of fracture healing and associated factors
大体时间:1 year
|
Assessment of the effect of osteoporosis treatment on fracture healing and the rate of refracture or new fractures.
|
1 year
|
|
Assessment of complications
大体时间:1 year
|
Perioperative and postoperative complications, including cement leakage, secondary lumbar spinal canal stenosis, intravertebral cleft (Kümmell disease), adjacent vertebral fractures, and pseudarthrosis (nonunion).
|
1 year
|
|
Assessment of treatment timelines
大体时间:1 year
|
ime intervals (in days) between fracture occurrence and MRI, between MRI and surgical consultation, and between fracture occurrence and definitive treatment.
|
1 year
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 38RC26.0185
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.